4166 Stock Overview
Engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Orient Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$38.35 |
| 52 Week High | NT$50.70 |
| 52 Week Low | NT$19.45 |
| Beta | 0.048 |
| 11 Month Change | 34.56% |
| 3 Month Change | 44.44% |
| 1 Year Change | 92.23% |
| 33 Year Change | 102.91% |
| 5 Year Change | 145.83% |
| Change since IPO | 1.76% |
Recent News & Updates
Shareholder Returns
| 4166 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 7.6% | 0.6% | -0.8% |
| 1Y | 92.2% | 9.2% | 29.0% |
Return vs Industry: 4166 exceeded the TW Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: 4166 exceeded the TW Market which returned 29% over the past year.
Price Volatility
| 4166 volatility | |
|---|---|
| 4166 Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4166's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 4166's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Chun-Tong Huang | www.oppharma.com |
Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson’s and Alzheimer’s diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and micro granules.
Orient Pharma Co., Ltd. Fundamentals Summary
| 4166 fundamental statistics | |
|---|---|
| Market cap | NT$8.79b |
| Earnings (TTM) | NT$119.10m |
| Revenue (TTM) | NT$1.07b |
71.8x
P/E Ratio8.0x
P/S RatioIs 4166 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4166 income statement (TTM) | |
|---|---|
| Revenue | NT$1.07b |
| Cost of Revenue | NT$480.45m |
| Gross Profit | NT$585.21m |
| Other Expenses | NT$466.12m |
| Earnings | NT$119.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.53 |
| Gross Margin | 54.92% |
| Net Profit Margin | 11.18% |
| Debt/Equity Ratio | 24.7% |
How did 4166 perform over the long term?
See historical performance and comparison